Cor Vasa 2021, 63(Suppl. 1):38-51

The year in cardiovascular medicine 2020: heart failure and cardiomyopathies

Héctor Bueno^{1, 2, 3, 4, *}, Brenda Moura^{5, 6}, Patrizio Lancellotti^{7, 8}, Johann Bauersachs⁹

¹ Multidisciplinary Translational Cardiovascular Research Group. Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro, 3, Madrid 28029, Spain;

² Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital, 12 de Octubre (imas12), Madrid, Spain;

³ Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Madrid, Spain;

⁴ Facultad de Medicina, Universidad Complutense de Madrid, Plaza de Ramón y Cajal, s/n, 28040 Madrid, Spain;

⁵ Cardiology Department, Military Hospital, Av. da Boavista S/N, 4050-115 Porto, Portugal;

⁶ CINTESIS-Center for Health Technology and Services Research, R. Dr. Plácido da Costa, 4200-450 Porto, Portugal;

⁷ Department of Cardiology, CHU SartTilman, University of Liège Hospital, GIGA Cardiovascular Sciences, Avenue de L'Hôpital 1, 4000 Liège, Belgium;

⁸ Cardiology Departments, Gruppo Villa Maria Care and Research, Maria Cecilia Hospital, Cotignola Bari, Italy and Via Corriera, 1, 48033 Cotignola RA, Italy and Anthea Hospital, Via Camillo Rosalba, 35/37, 70124 Bari BA, Italy

⁹ Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany

During year 2020, we learned new options to better stratify patients with heart failure and preserved left ventricular ejection fraction (HFpEF) (A), the clinical benefit of three new drugs to improve prognosis of patient with heart failure and reduced left ventricular ejection fraction (HFrEF): empagliflozin, vericiguat and omecamtiv mecarbil (B), the potential benefit of a broader utilization of recommended drugs for HFrEF in patients with left ventricular ejection fraction higher than 40% (C), and the potential added clinical benefit of a comprehensive use of recommended drugs for HFrEF (D) in a year marked by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic (central cartoon). Reprinted or adapted from: (A) Selvaraj et al.,²³ (B) Packer et al.,115 Armstrong et al.,¹²⁶ and Teerlink et al.,¹³² (C) Böhm et al.,¹⁰⁰ (D) Vaduganathan et al.¹³⁹ (Graphical Abstract – see in original.)

Klíčová slova: Heart failure, Epidemiology,  Clinical practice, Imaging, Biomarkers, Pharmacotherapy, Randomized control trials, SGLT-2 inhibitor, Angiotensin receptor-neprilysin inhibitors, Activators of soluble guanylate cyclase, Cardiac myosin activators and inhibitors, Telemedicine

Vloženo: 9. červen 2021; Přijato: 9. červen 2021; Zveřejněno: 1. červenec 2021  Zobrazit citaci